Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$162.11

0.11 (0.07%)

, BIIB

Biogen

$233.17

1.78 (0.77%)

11:40
04/04/19
04/04
11:40
04/04/19
11:40

Sage seen by sector advisor as 'good fit' for Biogen, Dealreporter says

Three sector advisors told Dealreporter that they believe Biogen (BIIB) could restock its development pipeline with late-stage acquisitions in the neuroscience and gene therapy areas. One advisor said that Sage Therapeutics (SAGE) "could be a good fit if Biogen wanted to make a big splash, but said that such large-scale M&A seems unlikely for the company," Dealreporter said, according to contacts. Sage Therapeutics shares saw a brief spike coincidental with the report from Dealreporter. In late morning trading, Sage shares are up 34c, or 0.2%, to $162.13.

SAGE

Sage Therapeutics

$162.11

0.11 (0.07%)

BIIB

Biogen

$233.17

1.78 (0.77%)

  • 08

    Apr

  • 24

    Apr

  • 30

    Apr

  • 01

    May

SAGE Sage Therapeutics
$162.11

0.11 (0.07%)

02/19/19
PIPR
02/19/19
NO CHANGE
Target $206
PIPR
Overweight
Piper sees 'significant unrealized value' in shares of Sage Therapeutics
Piper Jaffray analyst Danielle Brill keeps an Overweight rating on Sage Therapeutics with a $206 price target after the company reported fiscal 2018 results and an update on its pipeline. Enrollment in the SAGE-217 pivotal Phase 3 major depressive disorder trial is reportedly going well and top-line data are now expected by Q4 of 2019 or Q1 of 2020, Brill tells investors in a post-earnings research note. The analyst sees "significant unrealized value" for SAGE-217 and expects "various upcoming catalysts" to drive Sage shares higher.
02/22/19
GUGG
02/22/19
INITIATION
Target $205
GUGG
Buy
Sage Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Sage Therapeutics with a Buy rating and $205 price target, as he believes Zulresso and SAGE-217 have generated impressive data in PPD and MDD. The analysts, who thinks those drugs "have the potential to change the treatment paradigm for treating mood disorders," projects Zulresso and SAGE-217 could generate sales in the $3B-$5B range.
03/20/19
PIPR
03/20/19
NO CHANGE
Target $206
PIPR
Overweight
Sage Therapeutics approval in-line with expectations, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says FDA approval of Sage Therapeutics' Zulresso for postpartum depression, product labeling, and gross pricing of $34,000 are "entirely in-line with expectations." The analyst continues to believe the opportunity of a 60-hour intravenous infusion with restricted use is modest at $300M in peak sales. However, the commercial footprint Sage can establish with Zulresso should position the company well for maximal success with SAGE-217 in the postpartum depression setting, Brill tells investors in a research note. She reiterates an Overweight rating on the shares with a $206 price target.
03/20/19
HCWC
03/20/19
NO CHANGE
Target $254
HCWC
Buy
Ligand receives royalty on sales of Zulresso, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis points out that Ligand Pharmaceuticals (LGND) is entitled to a 3% royalty on the sales of Sage Therapeutics' (SAGE) Zulresso, which just received FDA approval. The approval also provides Ligand with a $3M milestone payment, Pantginis tells investors in a research note. The analyst thinks Zulresso "should maintain a comfortable niche" and he reiterates a Buy rating on Ligand with a $254 price target.
BIIB Biogen
$233.17

1.78 (0.77%)

03/25/19
HCWC
03/25/19
NO CHANGE
Target $300
HCWC
Buy
Biogen price target lowered to $300 from $363 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Biogen to $300 from $363 after the company and Eisai decided to stop clinical trials of aducanumab based on the futility results of the interim analysis of the Phase 3 trials. Investor focus will likely now shift to the pipeline growth and defense of Biogen's multiple sclerosis franchise, Fein tells investors in a research note. He thinks Spinraza should continue to drive revenue growth in the near-term and believes Biogen has sufficient financial means to continue investing in the pipeline to support the long-term growth of the company. The analyst keeps a Buy rating on the shares.
03/25/19
RBCM
03/25/19
NO CHANGE
Target $236
RBCM
Sector Perform
Biogen price target lowered to $236 from $318 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Biogen to $236 and kept his Sector Perform rating after the failure of its two Alzheimer's disease trials. The analyst notes that investors will now shift their focus towards the upcoming IP developments risks for Tecfidera and potential competition to its Spinraza, but also sees "few near-term opportunities to generate enthusiasm" for Biogen's ability to "fill the gap left by aducanumab and out-year loss of base business revenues."
03/26/19
PIPR
03/26/19
NO CHANGE
Target $280
PIPR
Overweight
Piper continues to recommend Biogen shares after deeper dive on BIIB067
Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares after a deeper dive on BIIB067, an anti-sense oligonucleotide targeting SOD1 for the treatment of SOD1-amyotrophic lateral sclerosis. With the recent discontinuation of aducanumab in mild Alzheimer's disease, the company's amyotrophic lateral sclerosis anti-sense oligonucleotide programs could help dispel the notion that Biogen has no pipeline, Raymond tells investors in a research note. He thinks the BIIB067 and BIIB078 programs could add $10 and $15, respectively, to the stock if successful. Raymond keeps an Overweight rating on Biogen with a $280 price target. The stock closed yesterday up $3.55 to $220.26.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Piper says AAN meeting should be 'meaningful' for Alexion, Biogen
Piper Jaffray analyst Christopher Raymond reported that the American Academy of Neurology posted emerging science abstract titles this morning, adding that full abstracts are not anticipated until May 3. It appears Phase 3 data on Alexion's (ALXN) Soliris for Neuromyelitis Optica Spectrum Disorder, or NMOSD, will be presented as an emerging science abstract and that data from a Phase 1/2 study of Biogen's (BIIB) BIIB067 in SOD1 mutant ALS patients will also be presented, making the meeting potentially "meaningful" for both. Raymond keeps Overweight ratings on Alexion and Biogen.

TODAY'S FREE FLY STORIES

CURO

Curo Group

$10.96

0.16 (1.48%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Curo Group management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 16

    May

  • 05

    Jun

  • 13

    Nov

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts Permits to be reported at 08:30 »

March Housing Starts…

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

AON

Aon plc

$175.38

-0.14 (-0.08%)

, MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Willis Towers Watson »

Analyst Klauber holds a…

AON

Aon plc

$175.38

-0.14 (-0.08%)

MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

WLTW

Willis Towers Watson

$177.37

0.45 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 20

    May

  • 11

    Jun

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

21:07
04/18/19
04/18
21:07
04/18/19
21:07
Recommendations
Intuitive Surgical analyst commentary at Piper Jaffray »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

UBER

Uber

$0.00

(0.00%)

, TM

Toyota

$125.10

0.93 (0.75%)

20:35
04/18/19
04/18
20:35
04/18/19
20:35
Hot Stocks
Uber confirms investment from Toyota, DENSO and SoftBank Vision Fund »

Toyota Motor (TM), Denso…

UBER

Uber

$0.00

(0.00%)

TM

Toyota

$125.10

0.93 (0.75%)

DNZOY

Denso

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

FIX

Comfort Systems USA

$57.58

0.06 (0.10%)

20:08
04/18/19
04/18
20:08
04/18/19
20:08
Hot Stocks
Comfort Systems USA discloses ransomware attack virus »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

19:29
04/18/19
04/18
19:29
04/18/19
19:29
Periodicals
Nissan to cut global output by 15% in FY19/20, Nikkei reports »

Nissan Motor (NSANY) will…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FE

FirstEnergy

$40.51

0.28 (0.70%)

19:13
04/18/19
04/18
19:13
04/18/19
19:13
Hot Stocks
FirstEnergy CEO 'pleased' FES submitted revised disclosure statement »

FirstEnergy Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

TSLA

Tesla

$273.25

2.13 (0.79%)

19:03
04/18/19
04/18
19:03
04/18/19
19:03
Periodicals
Tesla CEO, SEC granted one more week to resolve tweet dispute, WSJ says »

Tesla CEO Elon Musk and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

EXPO

Exponent

$56.39

0.23 (0.41%)

, AKRX

Akorn

$2.77

-0.16 (-5.46%)

18:57
04/18/19
04/18
18:57
04/18/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

EXPO

Exponent

$56.39

0.23 (0.41%)

AKRX

Akorn

$2.77

-0.16 (-5.46%)

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

FAST

Fastenal

$71.08

0.95 (1.35%)

APHA

Aphria

$7.65

-0.165 (-2.11%)

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

PBCT

People's United

$17.12

-0.21 (-1.21%)

I

Intelsat

$19.48

0.235 (1.22%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

PFE

Pfizer

$39.37

-0.5 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 16

    May

  • 18

    May

  • 05

    Jun

FIVE

Five Below

$141.65

1.82 (1.30%)

18:44
04/18/19
04/18
18:44
04/18/19
18:44
Hot Stocks
Five Below CEO: There is potential for 2,500+ stores in the U.S »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBRT

Liberty Oilfield Services

$16.60

-0.59 (-3.43%)

18:39
04/18/19
04/18
18:39
04/18/19
18:39
Hot Stocks
Liberty Oilfield Services CFO sells 90,000 Class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 01

    May

  • 22

    May

VNO

Vornado

$67.02

0.77 (1.16%)

18:37
04/18/19
04/18
18:37
04/18/19
18:37
Hot Stocks
Vornado sells 45% equity in flagship NYC assets to institutional investors »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 16

    May

CHKP

Check Point

$120.01

-9.56 (-7.38%)

18:26
04/18/19
04/18
18:26
04/18/19
18:26
Recommendations
Check Point analyst commentary at Jefferies »

Check Point billings,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

CAG

Conagra Brands

$30.53

0.405 (1.34%)

18:11
04/18/19
04/18
18:11
04/18/19
18:11
Hot Stocks
Conagra Brands director Gregor buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

UNP

Union Pacific

$176.70

7.5 (4.43%)

17:52
04/18/19
04/18
17:52
04/18/19
17:52
Periodicals
Union Pacific halts construction of $550M facility in Texas, WSJ reports »

Union Pacific has stopped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 16

    May

SO

Southern Company

$51.95

-0.22 (-0.42%)

17:47
04/18/19
04/18
17:47
04/18/19
17:47
Hot Stocks
Southern Company to sell Nacogdoches Generating Facility for $460M »

Southern Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 21

    May

  • 21

    May

TSLA

Tesla

$273.25

2.13 (0.79%)

17:46
04/18/19
04/18
17:46
04/18/19
17:46
Periodicals
Tesla CEO Musk, SEC ask for extension to settle tweet dispute, Reuters says »

Tesla CEO Elon Musk and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

GLD

SPDR Gold Shares

$120.40

0.09 (0.07%)

17:44
04/18/19
04/18
17:44
04/18/19
17:44
Hot Stocks
SPDR Gold Shares holdings fall to 751.68MT from 752.86MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSW

OneSpaWorld

$13.77

(0.00%)

17:37
04/18/19
04/18
17:37
04/18/19
17:37
Syndicate
Breaking Syndicate news story on OneSpaWorld »

OneSpaWorld files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:36
04/18/19
04/18
17:36
04/18/19
17:36
Hot Stocks
Charles Schwab EVP Murtagh sells 23.2K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

OSW

OneSpaWorld

$13.77

(0.00%)

17:36
04/18/19
04/18
17:36
04/18/19
17:36
Syndicate
Breaking Syndicate news story on OneSpaWorld »

OneSpaWorld files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$0.00

(0.00%)

17:32
04/18/19
04/18
17:32
04/18/19
17:32
Hot Stocks
Sears delays filing 10-K form »

As previously reported on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.